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Abstract 
Epidemiological evidence shows an inverse relationship between dietary fibre intake and body weight 
gain. Oat β-glucan, a soluble fibre alters appetite hormones and subjective satiety in acute meal test 
studies, but its effects have not been demonstrated with chronic consumption. The present study aimed 
to test the effects in women of two different doses of oat β-glucan on weight loss and hormones 
associated with appetite regulation. In a 3-month parallel trial, sixty-six overweight females were 
randomised into one of three 2 MJ energy-deficit diets: a control and two interventions including 5–6 g or 
8–9 g β-glucan. Anthropometric and metabolic variables (blood glucose level, insulin, total cholesterol 
(TC), LDL, HDL, TAG and leptin), together with markers of appetite regulation (cholecystokinin (CCK), 
glucagon-like peptide-1 (GLP-1), ghrelin, peptide YY (PYY) and PYY3-36) were measured at baseline and 
at 3 months. After 3 months, all groups lost weight (P < 0·001) and showed a reduced waist 
circumference (P < 0·001). The study sample also showed reductions in TC, LDL, HDL, leptin, PYY, GLP-1 
values (all P < 0·001) and an increase in CCK levels (P < 0·001). No significant differences were noted 
between the groups for all outcome values except PYY levels (P = 0·018). In broad terms, the addition of 
oat β-glucan did not enhance the effect of energy restriction on weight loss in mildly overweight women, 
although wide variations in observed results suggests that individual responsiveness may be an issue. 
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Epidemiological evidence shows an inverse relationship between dietary fibre intake and body weight gain. Oat b-glucan, a soluble fibre alters
appetite hormones and subjective satiety in acute meal test studies, but its effects have not been demonstrated with chronic consumption. The
present study aimed to test the effects in women of two different doses of oat b-glucan on weight loss and hormones associated with appetite
regulation. In a 3-month parallel trial, sixty-six overweight females were randomised into one of three 2 MJ energy-deficit diets: a control and
two interventions including 5–6 g or 8–9 g b-glucan. Anthropometric and metabolic variables (blood glucose level, insulin, total cholesterol
(TC), LDL, HDL, TAG and leptin), together with markers of appetite regulation (cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1),
ghrelin, peptide YY (PYY) and PYY3-36) were measured at baseline and at 3 months. After 3 months, all groups lost weight (P,0·001) and
showed a reduced waist circumference (P,0·001). The study sample also showed reductions in TC, LDL, HDL, leptin, PYY, GLP-1 values
(all P,0·001) and an increase in CCK levels (P,0·001). No significant differences were noted between the groups for all outcome values
except PYY levels (P¼0·018). In broad terms, the addition of oat b-glucan did not enhance the effect of energy restriction on weight loss in
mildly overweight women, although wide variations in observed results suggests that individual responsiveness may be an issue.
b-D-Glucan: Weight loss: Weight control: Appetite hormones
Large bodies of epidemiological data show an inverse
relationship between dietary fibre intake and body
weight(1 – 5) so that the logic and simplicity of including fibre
in an energy-controlled diet remains tantalising. As a com-
ponent of food, fibres are found in a fermentable (soluble)
or non-fermentable (insoluble) form, but early research has
been unable to show benefits from including either form in
short term (3–4 weeks) ad libitum diets(6). This was also the
case when the form of fibre was mixed linkage b-glucan, a
soluble fibre delivered by oats(7), well recognised for its
cholesterol(8) and glucose lowering(9) actions. In order to
better expose the advantages apparent from epidemiological
studies, more work is required in understanding the physical
features of fibre, the food delivery system, and how these
may work together to affect mechanisms associated with
weight management, such as satiety, particularly over longer
periods of time.
It is accepted that soluble fibre, by its viscous nature will
not only increase upper gastrointestinal transit time, but also
stimulate cholecystokinin (CCK) that will increase peristal-
sis(10). The effects of other hormones are less clear, but the
ileal brake formed by undigested foods in the distal gut
(occurring with high fibre foods), in addition to the fermenta-
tion of soluble fibres in the large bowel are all seen as positive
benefits of fibre. Meal studies are able to expose these mech-
anisms of action. This is done via assessment of biochemical
markers and subjective measures of satiety, in addition to
monitoring subsequent food intake after consumption of the
test food. Studies of b-glucan have identified doses as low
as 2 g may elicit acute lowering of glycaemia(11), while
others suggest a minimum of 4 g(10) may be required for
other gastrointestinal effects, such as those causing the release
of appetite hormones. However, meal test studies only define
an acute situation in very controlled conditions.
In addition to the time factor, the food delivery system
requires consideration. For example, the clinical effectiveness
of fibres such as b-glucan may be reduced in certain foods. It
has been shown that in bread making, endogenous enzymes in
the bread reduce the viscosity of the b-glucan thereby decreas-
ing its clinical effectiveness(12,13). However, a recent satiety
study(14) looking at high-dose (10 g) b-glucan and appetite
hormones has showed that a lower viscosity drink (with
viscosity lowered using b-glucanases) increased the levels of
certain appetite hormones such as CCK and glucagon-like
peptide-1 (GLP-1) compared with the high viscosity version
of the same drink. Nevertheless, such contrasts once again
do not define what may happen when soluble fibres are
consumed over time, as a change in hormones over a few hours
*Corresponding author: Eleanor J. Beck, fax þ61 2 4221 4844, email eleanor@uow.edu.au
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does not necessarily translate to appetite and weight changes
over a longer period of time.
The present study describes a 3-month randomised con-
trolled dietary intervention trial, designed to review the
specific effects of b-glucan from oat bran incorporated in
an energy-restricted meal plan. The primary outcome was
a difference in weight reduction between the control group
and intervention groups. Secondary outcomes included a var-
iety of biochemical measures linked with satiety or change
in body weight, subjective satiety measures and perceived
satisfaction with the product. Biochemical measures included
fasting glucose, insulin, cholesterol, LDL, HDL, TAG,
leptin, CCK, GLP-1, ghrelin, peptide YY (PYY) and
PYY3-36. We hypothesised that the subjects receiving
b-glucan would lose more weight than the subjects on the
control diet, and that changes in appetite hormones may




This was a 3-month parallel randomised controlled trial with
female subjects, based on evidence that they may exhibit
greater acute hormone changes with fibre intake(15). There
were three arms to the study with all the groups receiving
advice on energy restriction and all the subjects receiving
cereal products to include in their diets. The control group
had relatively high fibre products with no oat b-glucan,
while the intervention groups had similar products with
added b-glucan at a moderate (MBG; 5–6 g/d) and at a high
(HBG; 8–9 g/d) level. A sample size of twenty subjects per
group was based on data from a previous study showing a
1·8 kg difference between a group supplemented with
b-glucan and a control group, where both groups were con-
suming a energy-deficient diet(16). For a power of 80 %, seven-
teen subjects would be required in each group for this change
to be significantly different at an a level of 0·05 and recruiting
at least twenty subjects would allow for dropouts. Inclusion
criteria advertised in local media were 19–45 years of
age (pre-menopausal), BMI range from 25–32 kg/m2, non-
smokers, no known food allergies and of general good
health. The present study was conducted according to the
guidelines laid down in the Declaration of Helsinki and all
procedures involving human subjects were approved by the
University of Wollongong, Human Ethics Committee
(HE06/311). Written informed consent was obtained from
all the subjects. The trial was registered with the Australian
Clinical Trials Registry (ACTRN12607000126415).
The first seventy-seven of 215 enquiries were screened
resulting in randomisation of sixty-six subjects, using a com-
puter-generated sequence using random permuted blocks
(Fig. 1). All the subjects, but not dietitians were blinded to
their randomisation status within the trial. The subjects
attended the study centre for a total of five times. Visits
included collection of background dietary data using a vali-
dated diet history interview(17) and instruction on completion
of a 3-d weighed food record, collection of fasting blood
samples at baseline together with dietary education, two
follow-up dietary visits and collection of fasting blood
samples at 3 months. All the subjects had their height,
weight and waist circumference recorded at each visit to the
centre. The subjects were also contacted by telephone on
one occasion in between the monthly visits to provide dietary
review and support. Visual analogue scales (VAS) related to
appetite(18), food records and the Baecke Physical Activity
Questionnaire(19) were all completed at baseline, half-way
through the study and within the final week of the study.
For the VAS, the subjects recorded their feelings on individual
forms at six different time points throughout the day: immedi-
ately before each of the three main meals and 2 h after each of
these meals. Markings by participants were measured in
millimetres. All nutritional analysis was performed using
FoodWorks 2007, version 5 (Xyris Software, Brisbane,
QLD, Australia) with nutrient contents of study foods added
as required.
Dietary intervention
A basal metabolic requirement for energy was calculated for
each subject using the Schofield equation using BMI equal
to 25 kg/m2. A low activity factor (1·3) was chosen to estimate
energy requirements and then 2000 kJ was subtracted from this
level to a calculated weight loss of 0·5 kg/week. Intervention
diets were designed to control for all macronutrients with
the only variation in total fibre, primarily b-glucan such that
a typical diet, as described in Table 1 only varied in the
trial products given. Product development for cold and hot
cereals as well as additional snack items took place in a
pilot processing plant by qualified cereal food technologists.
The source of b-glucan was a commercially available oat
bran with 22 % b-glucan. The subjects were instructed to eat
the cereal provided at breakfast (ready-to-eat (RTE) cereal
or porridge) and two snack items at afternoon tea (choice
of two muesli bars, two cereal snack packs or one muesli
bar and one cereal snack pack). Product consumption was
evaluated for overall satisfaction, and positive and negative
symptoms were observed using questionnaires at the completion
of the study.
Products were tested for molecular weight, solubility,
viscosity and both soluble and total b-glucan using methods
described by Tosh et al. (20). The amount of b-glucan in the
control products was negligible (,0·2 g/serving). b-Glucan
contents of the products, including soluble b-glucan are
included in Table 2. The b-glucan in the RTE cereal and
snack products had a higher solubility than the other products,
with solubility improved by extrusion (porridges not
extruded). The molecular weight of b-glucan extracted from
all of the products showed only limited decreases due to
effects of processing; highest where there was least processing
(muesli bars and porridge) and lower in the extruded products
(RTE cereal and cereal snack). The cereal and porridge
samples with lower b-glucan contents (MBG samples) pro-
duced lower viscosity extracts (Table 2). The viscosity profiles
of the HBG muesli bar and the HBG porridge had extracts
with very similar viscosity profiles despite their differences
in total b-glucan content. This is due to the greater solubility
of the b-glucan in the muesli bar. The HBG RTE cereal
had the greatest viscosity due to its high b-glucan and high
solubility. All of the intervention products showed physico-
chemical characteristics which would be expected to produce

















bioactivity. These products should have increased viscosity in
the upper digestive tract which should modify the digestion
and absorption rates of the nutrients.
Clinical indices
Fasting blood samples at 0 and 3 months were collected
using Sarstedte Monovette blood collection tubes. Glucose,
insulin, total cholesterol, HDL, LDL and TAG analysis was
performed at an accredited pathology laboratory (Southern
IML Pathology, Wollongong, NSW, Australia). A further
sample was collected into tubes containing potassium
EDTA (to achieve a concentration of 0·5–2 mg EDTA/ml
of blood after collection). Both the tubes contained dipeptidyl
peptidase IV (Millipore, Billerica, MA, USA) to level of
10ml/ml of blood. One tube also contained aprotinin equival-
ent to 0·6 trypsin inhibitor units per ml of blood (Aprotinin
from bovine lung Sigma Aldrich A1153 dissolved in
normal saline with 0·9 % benzyl alcohol) for analyses of
CCK and PYY3-36. Together with the dipeptidyl peptidase
IV inhibitor, the second tube contained 240ml of complete
protease inhibitor cocktail (Roche, Castle Hill, NSW, Austra-
lia) made to 25 £ concentration in distilled water. Final con-
centrations met the recommendations for the manufacturers’
protocols for assays described later. The blood samples
were then centrifuged at 48C for 15 min at 1500 g. The
plasma was stored at 2808C until further analysis could be
completed.
Ghrelin, leptin, GLP-1 and total PYY were analysed using
a Lincoplexe Human Gut Hormone Panel (catalogue no.
HGT-68K) according to manufacturer’s instructions.
CCK analysis used Phoenix Peptidese RIA (RK-069-04)
for CCK octapeptide (CCK 26-33). The standard RIA protocol
was applied but without extraction of the peptides before the
Fig. 1. Flow diagram of participation in the study. MBG, mid-dose b-glucan; HBG, high-dose b-glucan.

















assay. PYY3-36 analysis utilised a human specific RIA sourced
from Linco (PYY-67HK) using the standard protocol.
Statistical analysis
Data for all anthropometry, blood analysis, VAS measure-
ments and dietary intake were entered into SPSS for windows,
version 15.0 (SPSS 15.0, Chicago, IL, USA). Repeated
measures ANOVA (RMANOVA) using the general linear
model with group (control, MBG and HBG) as the between-
subjects factor, was used to identify primary changes in
each parameter over time and also differences between the
groups. Post hoc analysis using Bonferroni adjustments was
reviewed to detect specific differences between the control
and intervention groups. Log (base 10) transformations were
also used as appropriate. Regression analysis was used to
identify correlations between group anthropometric and bio-
chemical indices. One-way ANOVA was used to review
VAS and Baecke questionnaire results at various time points
identifying any differences between the groups.
Results
Baseline data
Final numbers in each group were sixteen controls, twenty-one
MBG and nineteen HBG (Fig. 1). There were two withdrawals
from each of the MBG and HBG groups, but six were from the
control group. Fifty-six subjects were included in the final data
analysis. Some subjects did not complete all forms or blood
was unable to be drawn for certain tests, so numbers in each
calculation varied.
At baseline, there were no significant differences between
group anthropometric and metabolic measures (Table 3).
The subjects were overweight but overall they were not hyper-
lipidaemic (mean cholesterol 5·03 (SD 1·07) mmol/l). The only
baseline biochemistry measure which showed significant
differences between the groups was the fasting blood glucose
level (P¼0·046), where the level for the HBG group was
lower than that of the other two treatments (Table 3).
Review of food records and diet histories at baseline indi-
cated relatively well-matched groups. No significant differ-
ences were noted between energy, fibre, protein, fat or
carbohydrate overall (Table 4). The only significant difference
at baseline was the amount of MUFA consumed (P¼0·025),
where post hoc analysis using Bonferroni adjustments
showed significantly less MUFA in the MBG group (24·8
(SD 9·8) g) compared with the control (32·5 (SD 8·0) g). The
MUFA intake of the HBG group (28·8 (SD 6·8) g) was between
these two levels.
Dietary intervention
Evaluation of the food records at mid-way through the study
and at the end indicated little variation between the groups
for macronutrient intakes at each time point with no signifi-
cant differences between the groups. Review of the overall
dietary composition of baseline diets compared with the
mid-point of the study and the 3-month end-point showed a
decrease in percentage energy from fat and an increase in
the percentage energy from protein and carbohydrate (Table 4).
General compliance with a weight reduction regimen was
identified by overall weight loss (described later) and
energy restriction detailed in the food records. Total energy
Table 1. Food serves for typical dietary study participant
Food group Serve size Number of serves/d
Breads/cereal/starchy vegetables 1 slice bread or 1/2 cup pasta or 1 medium potato 4 serves
Other vegetables 1/2 cup cooked ¼ 1 cup raw 2·5 cups cooked or 5 cups raw
Fruit 1 piece fresh or 3/4 cup canned 2 pieces
Milk/alternatives 150 ml light/200 ml skim, 100 g low-fat yoghurt 2–3 serves
Meat/alternatives 30 g meat/45–60 g fish/20 g low-fat cheese 3–4 serves
Fats 1 tsp oil or margarine or 1 tbsp avocado 3–4
Control or intervention products Portion controlled pre-packed Cereal þ 2 snacks (muesli bar or snack pack of cereal)
tsp, tea spoon; tbsp, table spoon.










Control RTE cereal Negligible Negligible Not done 4·0
Control Porridge Negligible Negligible Not done 1·2
Control Extruded snack Negligible Negligible Not done 0·6
Control Muesli bar Negligible Negligible Not done 2·9
MBG RTE cereal 2·3 3·9 14·6 7·4
MBG Porridge 1·2 3·0 19·0 6·6
HBG RTE cereal 3·5 4·8 83·9 10·1
HBG Porridge 1·7 4·4 58·9 9·7
HBG Extruded snack 1·4 2·1 54·5 4·4
HBG Muesli bars 0·9 1·7 57·0 4·6
RTE, ready-to-eat; MBG, mid-dose b-glucan; HBG, high-dose b-glucan.

















intake was significantly lower at the mid-point (mean 6308
(SD 1068) kJ) of the trial and the end-point (mean 6000
(SD 1163) kJ) (P,0·001) compared with the baseline (mean
8725 (SD 1703) kJ) using RMANOVA with fibre level as the
between-group effect and time as the within-subject variant.
There was no interaction effect over time (P¼0·192) indicat-
ing all the groups followed the energy-restricted diet to the
same extent.
Dietary compliance with the study products measured by
review of 3-d food records indicated that the use of breakfast
cereal was very high (90 % consumed), while compliance with
the snacks was reasonable (74 % consumed). Differences in
dietary fibre intakes between the groups could be accounted
for by the difference in fibre between the groups’ product
supply. This includes both soluble (b-glucan) and insoluble
fibre from the products. The groups achieved a significant
difference in the amounts of dietary fibre consumed at mid-
point (P,0·001, RMANOVA) and the last week of the
study (P,0·001, RMANOVA; Table 4). There was limited
change in the control group, indicating that the products sup-
plied to the subjects (which especially in the case of the cereal
were relatively high fibre) replaced foods of similar fibre
content.
The only dietary variation between the groups was the mono-
unsaturated fats which varied at baseline also. The levels were
not different at mid-point and at 3 months, but rather the
change from baseline produced an interaction effect for time £
group (Table 4). Therefore, all anthropometric and biochemical
results were also checked for correlation with the monounsatu-
rated fat levels.
There were no significant differences in activity scores
between the groups at any time point, indicating that changes
in physical activity were not a factor in influencing other
results.
Clinical indices
Almost all anthropometric and biochemical indices changed
over time, although there were no significant differences
between the groups for any measured clinical parameter
over time (Table 5). The average weight loss for the study
sample of 4·1 kg was significant (P,0·001; ranging from a
0·2 kg gain to a 14·9 kg loss). However, this is less than the
anticipated 6–6·5 kg designed for the energy-restricted diet.
It is also less than the change in kilojoule intake demonstrated
in the food records would predict. The weight loss was not sig-
nificantly different between the groups (P¼0·921). Waist
measurements decreased significantly (P,0·001).
Fasting blood glucose results did not decrease, however,
fasting insulin decreased significantly compared with baseline
(P,0·001). However, no differences between the groups were
identified (P¼0·184; Table 5). Log transformation of insulin
data showed the difference from baseline to 3 months was
still significant (P¼0·001) but not related to the intervention
(P¼0·113).
Regression analysis indicated that weight loss significantly
predicted waist change (P¼0·001), leptin (P¼0·007), blood
glucose level (P¼0·031) and insulin (P¼0·052). However,
the predictions, other than the expected waist change
(R 2 0·480) were relatively weak (R 2 0·130, 0·084 and 0·069,
respectively). Adjusting changes in these parameters for
weight loss, failed to identify any significant differences
between the groups.
Lipid results were examined overall, between the groups
and also reviewing data for those subjects who had elevated
lipids at baseline. The reduction in total cholesterol was not
significantly different between the groups, with mean
decreases of 0·19 (SD 0·79), 0·31 (SD 0·55) and 0·56 (SD
0·61) mmol/l for the control, MBG and HBG, respectively
(P¼0·239). The general trend was as expected with the great-
est decrease in cholesterol with the highest dose of b-glucan.
Overall, there was a significant decrease in cholesterol over 3
months (P,0·001).
For all the subjects, HDL levels significantly decreased over
time (P,0·001), LDL significantly decreased (P¼0·028) and
TAG did not change (P¼0·353). Although the LDL results for
RMANOVA did not show an overall effect between the
groups, post hoc Bonferroni adjustments indicated a trend to
differ between the control and high dose of b-glucan
(P¼0·077) with the greatest decrease in LDL in the HBG
group (Table 5). No significant (P,0·05) differences were
detected between the groups for the other lipid parameters.
Large standard deviations existed within all the datasets
limiting the significance of results, especially hormonal
Table 3. Baseline characteristics of study subjects
(Mean values and standard deviations)
Control (n 16) MBG (n 21) HBG (n 19)
Variable Mean SD Mean SD Mean SD P
Age (years) 37·1 5·6 37·7 6·0 37·4 5·5 0·96
Weight (kg) 77·0 7·8 80·9 8·2 77·6 6·5 0·17
BMI (kg/m2) 29·2 2·2 29·3 2·2 29·3 2·1 0·86
Waist (cm) 83·8 5·7 85·1 8·0 82·4 5·6 0·29
Fasting blood glucose (mmol/l) 4·7 0·6 4·9 0·5 4·5 0·4 0·05*
Fasting insulin (mU/l) 10·7 4·3 11·1 5·8 12·1 4·8 0·57
Cholesterol (mmol/l) 5·2 0·7 5·0 1·1 4·9 1·3 0·73
LDL (mmol/l) 3·2 0·5 2·9 1·0 2·7 0·9 0·17
HDL (mmol/l) 1·6 0·4 1·6 0·3 1·7 0·3 0·63
TAG (mmol/l) 1·3 0·4 1·1 0·5 1·0 1·0 0·55
MBG, mid-dose b-glucan; HBG, high-dose b-glucan.
* Significant value was measured using ANOVA.

















Table 4. Reported energy and macronutrient intakes at baseline, mid-point and at 3 months, with P values for repeated-measures ANOVA between groups
(Mean values and standard deviations)
Baseline Mid-point 3 months
Control MBG HBG Control MBG HBG Control MBG HBG P-values
Variable Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Group Time Interaction
Energy
(kJ)
9229 1419 8394 2122 8213 1284 6060 910 6480 1080 6008 1060 6090 1089 6193 1226 5496 1108 0·106 ,0·001* 0·192
Protein
(%E)
18·6 3·5 18·5 5·1 17·6 5·6 20·6 2·7 21·3 3·7 21·8 6·1 19·3 3·6 20·6 3·7 21·3 3·7 0·411 ,0·001* 0·363
CHO
(%E)
42·9 6·5 42·0 16·4 42·1 8·8 50·3 7·7 44·7 8·8 47·5 8·1 50·3 11·2 45·2 4·3 49·3 10·4 0·217 ,0·001* 0·842
Total fat
(%E)
34·9 19·0 32·1 10·1 34·3 9·1 22·6 8·8 27·0 8·9 23·5 7·2 22·4 7·9 26·9 6·5 22·7 8·4 0·321 ,0·001* 0·062
SFA
(%E)
13·3 3·8 12·7 5·0 14·5 3·8 8·4 3·2 9·5 4·0 8·7 3·3 8·6 3·8 9·7 2·5 7·9 3·2 0·547 ,0·001* 0·217
PUFA
(%E)
4·6 1·4 4·4 1·7 5·2 1·8 3·7 1·6 4·2 0·6 3·5 1·2 3·6 1·6 4·0 1·3 3·8 1·3 0·458 ,0·001* 0·202
MUFA
(%E)




21·9 4·6 21·2 6·0 20·5 6·8 24·2 5·4 28·0 4·2 34·1 6·9 21·6 4·5 27·4 5·6 33·0 3·9 ,0·001* ,0·001* ,0·001*
E, energy; CHO, carbohydrate.


















British Journal of Nutrition
Table 5. Changes in clinical indices overtime and between control, mid-dose b-glucan (MBG) and high-dose b-glucan (HBG) groups
(Mean values and standard deviations)
All groups Control MBG HBG
Mean change Baseline Mean change Baseline Mean change Baseline Mean change
Changes in clinical indices Baseline data Mean SD P* Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD P†
Weight (kg) 78·4 24·1 3·1 ,0·001 77·6 7·8 2 4·0 2·4 80·9 8·23 2 4·3 3·7 76·6 6·5 2 3·9 2·9 0·921
Waist (cm) 83·8 2 4·1 2·8 ,0·001 83·8 5·7 2 4·0 2·6 85·3 7·9 2 0·8 3·16 82·0 5·5 2 3·4 2·5 0·476
Glucose(mmol/l) 4·72 0·02 0·47 0·586 4·75 0·57 2 0·01 0·41 4·89 0·46 0·03 0·43 4·52 0·37 0·15 0·55 0·420
Insulin (mmol/l) 11·37 2 2·68 3·75 ,0·001 10·74 4·29 2 3·16 4·59 10·92 5·70 2 1·42 3·11 12·40 4·83 2 3·40 3·50 0·184
Cho (mmol/l) 5·03 2 0·37 0·65 ,0·001 5·21 0·73 2 0·19 0·79 5·02 1·07 2 0·31 0·55 4·91 1·30 2 0·56 0·61 0·239
HDL (mmol/l) 2·91 2 0·23 0·2 ,0·001 1·59 0·38 0·24 0·10 1·64 0·27 2 0·16 0·19 1·70 0·33 2 0·3 0·25 0·091
LDL (mmol/l) 1·65 2 0·14 0·48 0·028 3·23 0·47 2 0·13 0·54 2·89 0·99 2 0·08 0·50 2·67 0·92 2 0·23 0·42 0·692
TAG (mmol/l) 1·11 2 0·09 0·43 0·353 1·27 0·40 2 0·05 0·29 1·06 0·49 2 0·13 0·26 1·03 0·98 2 0·01 0·72 0·688
Ghrelin (pg/ml) 53·4 2 6·4 29·5 0·217 45·4 21·0 2 6·9 18·7 65·0 72·9 2 9·3 33·9 47·2 29·6 0·0 33·8 0·957
Leptin (pg/ml) 20 620 2 7130 5720 ,0·001 18 690 9340 2 7050 6470 20 300 9160 2 5340 4820 22 610 6510 2 9430 5390 0·078
GLP (pg/ml) 47·95 2 6·9 9·3 ,0·001 49·6 16·7 2 7·7 9·5 50·3 15·0 2 8·0 8·9 43·8 14·6 2 5·0 9·7 0·493
PYY (pg/ml) 85·80 2 12·0 26·2 0·015 92·4 32·1 2 5·6 11·8 89·1 19·7 2 23·4‡ 31·5 77·1 32·9 2 1·3‡ 19·6 0·018
PYY3-36 (pg/ml) 73·23 6·1 21·0 0·195 71·4 11·7 2·5 18·2 71·0 19·8 10·1 18·4 77·3 25·1 8·9 25·8 0·807
CCK (pg/ml)§ 218 177 170 ,0·001 186 167 219 147 245 159 139 171 210 171 186 187 0·253
Cho, cholesterol; GLP, glucagon-like peptide; PYY, peptide YY; CCK, cholecystokinin.
*P values for ANOVA for change from 0 to 3 months.
†P values for repeated-measures ANOVA for changes between groups.
‡P#0·05 when compared to control using Bonferroni adjustments. No significant difference existed between MBG and HBG.
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changes. The decrease in leptin levels for the study sample
was significant over time (P,0·001) and regression analysis
indicated the association with decreasing body weight
(P¼0·007). Between the groups, the differences approached
significance (P¼0·078) with the greatest decrease in leptin
identified in the HBG group, even with the same body
weight change.
Total PYY levels decreased significantly over time
(RMANOVA, P¼0·015), and this was significantly different
between the groups (P¼0·041). Post hoc Bonferroni adjust-
ments indicated that the control group produced significantly
different effects compared with both the MBG (P¼0·021)
and HBG (P¼0·050) groups, where the smallest decrease
in PYY was seen in the HBG group. The greatest change
was in the MBG group so this would not seem related to
dose of b-glucan. Even though levels of total PYY decreased
in all the groups those for PYY3-36 increased, although the
latter were not statistically significant (P¼0·195). PYY3-36
levels increased more with the inclusion of b-glucan in the
diet (8–10 pg/ml increase compared with 2·5 pg/ml in the
control), but this was not significant between the groups
(P¼0·807).
There was a significant decrease in GLP-1 over time
(P,0·001) but no differences between the groups
(P¼0·567). Ghrelin levels did not significantly alter over
time (P¼0·217) and there were no between-group effects
(P¼0·632). CCK results seemed elevated most likely due to
a lack of extraction of peptides, however, as this was a
repeated-measures analysis, results were included. CCK
levels increased significantly over time (P,0·001) but there
was no group effect (P¼0·969) with all the groups increasing
the CCK levels at equal rates.
All variables were reviewed adjusting for weight loss and
monounsaturated fat, but other than the correlations described
previously, no significant trends were noted. The large stan-
dard deviations indicated that individual fluctuations are
more varied than any overall effect of increased b-glucan.
Subjective satiety
VAS results were reviewed for individual time points to
compare any differences which may have existed between
the control and test groups (ANOVA). No significant differ-
ences were identified between the groups at any time point
tested – that is all individuals showed similar hunger/fullness
at the same test points (data not shown).
Product evaluation
The majority of subjects in the intervention groups reported
some negative physical symptoms from the products (52 %
for MBG and 63 % for HBG), although this was less than
the numbers experiencing positive symptoms (67 % for
MBG and 85 % for HBG). Negative symptoms included
abdominal pain and changes in bowel patterns (both increased
and decreased stool frequency). Positive associations with the
study products included ‘feeling more full, for longer’,
‘healthy snacking avoiding unhealthy snacking’, ‘less peaks
and lows’ in intake, ‘more regular bowel movements’ and
‘increased energy’. The products were also evaluated from
an organoleptic perspective using questionnaires with Likert
scales. Overall, all the RTE cereal products received favour-
able evaluations. The porridges overall were disliked and
were consumed at a minimal level.
Discussion
Within the context of the present study, regardless of the diet
subjects were on, they lost weight, with the expected changes
in waist circumference, fasting insulin(21), lipids(22) and
leptin(23). Even though weight loss was modest, the change
of 5 % if maintained even at 3–4 % would most likely
decrease the incidence of development of type 2 diabetes in
this moderately overweight group, but at risk group(24). The
waist circumference of the group as a whole decreased signifi-
cantly and as a measure of abdominal adiposity indicated
decreased risk of insulin resistance, glucose intolerance and
dyslipidaemias(25,26). The fact that the subjects were only
moderately overweight with limited progression towards
metabolic syndrome, most likely limited the ability of the
study to differentiate subtle differences that may have existed
between the groups. Nevertheless, energy restriction alone
remained effective for weight loss.
Much of the research with b-glucan as a functional ingredi-
ent focuses on improvements in parameters, such as glycaemic
control and hypercholesterolaemia. The research here used
healthy subjects whose ‘healthy overweight’ status ensured
some elevated lipids but minimal insulin resistance. Greater
effects may have been seen in a population with diabetes
with greater metabolic dysfunction. Effects of b-glucan in a
more overweight or obese sample with or without energy
restriction cannot be inferred from the present study. The
change in cholesterol, greatest for the HBG group may have
been more exposed with more subjects, but this was a second-
ary outcome measure. Some literature on non-hypercholester-
olaemic or mildly hypercholesterolaemic individuals tends to
show limited response to b-glucan, so that the borderline sig-
nificance of results would be expected, particularly given the
observed weight loss. Greater than 10 % decrease in the
HBG group together with evidence from other studies(27)
still provides support for oat b-glucan as a dietary intervention
agent in the management of hypercholesterolaemia. The
observed decrease in HDL levels was unexpected, but the
reported consumption of saturated fats was notably higher
than polyunsaturated fats (Table 4), so the background diet
may not have been favourable.
With the modest weight loss demonstrated here, there were
still significant changes in PYY and GLP-1. Additionally,
there was an overall decrease in PYY while maintaining
or perhaps increasing the fractions involved with satiety
PYY3-36. It has been postulated that PYY has a role in the
aetiology of human obesity due to negative correlation with
BMI and the fact that injection of the active fraction of
PYY, PYY3-36 decreases food intake in human subjects
(28).
PYY is secreted in the same gut endocrine cells as GLP-1;
both inhibit gastric emptying and promote satiety and are
released in response to food. GLP-1 having an additional or
additive role in its regulation of blood glucose via increasing
insulin sensitivity(29).
The observed relationship between changes in hormones
and weight loss was perplexing. Nevertheless, recent research
has shown that with a very large weight loss, as seen in

















surgical interventions for obesity, fasting levels of PYY
increase but GLP-1 decreases, suggesting a less easily defined
relationship between the two hormones and that they are not
co-dependent(30). Studies using hypoenergetic diets to induce
weight loss have identified a decrease in GLP-1 response to
dietary stimulus with weight loss(31).
In clinical trials, fasting PYY and often PYY3-36 have been
shown to be decreased in obesity. Roth identified decreased
PYY3-36 in obese children, which increased with weight loss
and showed that this increase was predictive of successful
weight maintenance(32). Pfluger et al. (33) found no difference
in fasting PYY3-36 between lean and obese subjects, however,
identified a 30 % decrease in fasting total PYY when obese
subjects lost approximately 5 % of their body weight. The
results from the present study broadly mimic these results
with an overall decrease in PYY, but an increase or at least
maintenance in PYY3-36. Animal studies in our laboratory
(unpublished results) have indicated an increase in PYY3-36
with increasing doses of b-glucan, and the trend in the present
study warrants further investigation.
The group effect noted in fasting PYY, where both MBG
and HBG results are different from the control, is difficult
to interpret, given the smallest decrease was in the HBG
and the largest decrease in the MBG. Other results which
show similar trends (MBG a greater difference in one direc-
tion compared with the control or HBG such as with leptin)
do not show significant correlations with the PYY results so
it is difficult to infer a mechanism based on a U-shaped
curve, where a certain dose would produce negative results
but a greater dose would achieve desired outcomes. For
example, in the present study no correlations existed with
monounsaturated fat intake that was highest in the MBG
group, so that the differences may just be statistical aberra-
tions, in part created by the large variations in responses.
Similarly, the larger change in leptin in the HBG group
with the same weight loss seems positive, but the smallest
change was with the MBG group and no dietary correlations
exist.
We found a high overall acceptance of the high doses of
fibre and good maintenance of the solubility, molecular
weight and viscosity of the b-glucan after processing. No
differences were identified with the subjective measures of
satiety. The use of VAS is most likely to be accurate in a
controlled situation such as in acute meal test studies in a
laboratory situation(18). So it is perhaps not surprising that
small differences from month to month are unlikely to be
quantified by the subjects using the scales.
Despite attention to product attributes that theoretically
affect satiety and tight dietary controls, the present study
failed to confirm direct effects of set levels of b-glucan on
weight loss in an energy-restricted diet. Epidemiological
evidence strongly suggests that high fibre diets have positive
effects on weight control(34). Separating out the effects of a
single fibre remain a difficult task within an human interven-
tion trial, and it would seem the major outcomes in the present
study are similar to another recent intervention trial with
soluble fibre(35) that also could not find an intervention
effect with respect to weight loss. The lack of positive results
such as these could certainly be used to support the notion that
‘fibre’ is not just an indigestible ingredient in a food but is a
part of healthy diet that includes wholegrains, fruits and
vegetables perpetuating good health. However, there are a
number of confounding variables in the present study, which
warrant consideration.
First the current trial was only of 3 months duration. Studies
identifying positive effects of fibre, such as decreased weight
gain usually last for a number of years(4). A 3-month interven-
tion may not be long enough to separate out the differences
between the subjects’ desire to comply and the actual effects
of the dietary intervention. This difference is more likely to
be obvious if the subjects were to follow a particular eating
pattern over a longer timeframe. In a recent study, researchers
have found that regardless of the dietary intervention, subjects
who reported greater compliance with a weight loss regimen
have lost a greater amount of weight(36). The authors conclude
that strategies to increase adherence may be more important
than dietary composition.
Second, the present study included products for the control
group, which were still relatively high in fibre. Only the
amounts of b-glucan varied within the diet. It seems likely
that the effect of any one ingredient, even if positive, will
be relatively small and hence showing a statistical difference
between the groups will be difficult, especially over only
3 months. The numbers of subjects identified as necessary to
detect a difference in the present study was based on the
work of Solum(16), who used an energy-restricted diet with
overweight women to determine the possible benefits of
fibre supplementation. Control subjects used placebo tablets,
while the intervention group had approximately 6 g of fibre
sourced from grains and citrus fruit fibres. Over 12 weeks,
the intervention group lost 1·8 kg more. The way the subjects
consumed the fibre in the Solum study (capsules with water
just before each meal) may have affected the outcomes. The
overall greater weight loss of 6·7 and 8·5 kg for the control
and intervention groups, respectively in this supplement
study shows that adding food items to a dietary regimen
(as in the currently reported study) may decrease weight loss
to some degree. However, insisting subjects ate particular
breakfast and afternoon tea items may have increased energy
consumption at times when the subjects may have chosen to
eat less in a non-directed environment.
Finally, it is difficult to control the intake of human
subjects. Although food records and subjective discussions
with the subjects indicated high compliance with consumption
of study products overall, the subjects were less compliant
with the energy restriction as evidenced by the modest
weight loss. The greatest number of subjects withdrew from
the control group, which could infer the greatest difficulty
with compliance and a positive benefit of b-glucan, but this
is unable to be confirmed within the constraints of the ethical
requirements of the intervention trial.
In summary, although the groups experienced general
improvement in measures such as fasting insulin and choles-
terol, associated overall with weight loss, no effects seem
specifically related to b-glucan dose. Most likely, some differ-
ences would have been realised if the study continued in the
longer term, as generally, the subjects with higher fibre intakes
will maintain weight more easily. However, within the time-
frames of an intervention trial, and realistically, the time
frames individuals may pursue a ‘weight loss diet’, there
were no discernable differences between a regular energy-
restricted diet and that which contained significant b-glucan.
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